CD6-话题@MedSci - 梅斯（MedSci）

#CD6#

9篇内容 | 1043人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2058323, encodeId=306220583230a, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=病例报告：抗CD6抗体治疗COVID-19病人细胞因子释放综合征, objectType=article, longId=217559, objectId=a97c21e559fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a97c21e559fd, replyNumber=0, likeNumber=74, createdTime=2021-10-24, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a97c21e559fd, moduleTitle=病例报告：抗CD6抗体治疗COVID-19病人细胞因子释放综合征, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=a97c21e559fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058321, encodeId=13132058321eb, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=Br J Cancer：新型CD63–BCAR4融合蛋白可促进肺腺癌的致瘤性和转移, objectType=article, longId=203657, objectId=d34920365e0b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d34920365e0b, replyNumber=0, likeNumber=97, createdTime=2021-07-26, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d34920365e0b, moduleTitle=Br J Cancer：新型CD63–BCAR4融合蛋白可促进肺腺癌的致瘤性和转移, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=d34920365e0b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058322, encodeId=fc932058322c0, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标, objectType=article, longId=208290, objectId=058f2082904e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=058f2082904e, replyNumber=0, likeNumber=77, createdTime=2021-12-21, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=058f2082904e, moduleTitle=Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=058f2082904e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058320, encodeId=96532058320a9, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=2019年ACR：Equillium发表有关狼疮性肾炎中CD6-ALCAM途径的新见解, objectType=article, longId=182550, objectId=20b51825508f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=20b51825508f, replyNumber=0, likeNumber=76, createdTime=2019-11-26, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=20b51825508f, moduleTitle=2019年ACR：Equillium发表有关狼疮性肾炎中CD6-ALCAM途径的新见解, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=20b51825508f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058318, encodeId=ba9a20583183b, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=JCLA：CD62P和P10是评价血液透析治疗终末期肾病疗效的预测指标, objectType=article, longId=167629, objectId=55f016e6293d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55f016e6293d, replyNumber=0, likeNumber=83, createdTime=2019-06-11, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55f016e6293d, moduleTitle=JCLA：CD62P和P10是评价血液透析治疗终末期肾病疗效的预测指标, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=55f016e6293d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058319, encodeId=f760205831963, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=非控制性哮喘治疗的CD6靶向抗体Itolizumab的Ib期临床试验正式开始, objectType=article, longId=175281, objectId=383b1e52811e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=383b1e52811e, replyNumber=0, likeNumber=82, createdTime=2020-02-04, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=383b1e52811e, moduleTitle=非控制性哮喘治疗的CD6靶向抗体Itolizumab的Ib期临床试验正式开始, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=383b1e52811e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058317, encodeId=cd5e205831ead, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=Circulation：淋巴细胞上的氧化低密度脂蛋白受体（CD69）可预防动脉粥样硬化，预测亚临床疾病, objectType=article, longId=157911, objectId=37c215e91196, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=37c215e91196, replyNumber=0, likeNumber=66, createdTime=2019-05-02, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=37c215e91196, moduleTitle=Circulation：淋巴细胞上的氧化低密度脂蛋白受体（CD69）可预防动脉粥样硬化，预测亚临床疾病, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=37c215e91196)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058316, encodeId=a61d205831676, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=J Exp Med：CD68——抗疟疾药物治疗的新靶点, objectType=article, longId=54183, objectId=4e0254183f4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4e0254183f4, replyNumber=0, likeNumber=89, createdTime=2015-10-13, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4e0254183f4, moduleTitle=J Exp Med：CD68——抗疟疾药物治疗的新靶点, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=4e0254183f4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2058315, encodeId=363820583150f, content=<a href='/topic/show?id=e8254354e7' target=_blank style='color:#2F92EE;'>#CD6#</a>, objectTitle=外周血T淋巴细胞CD69在狼疮性肾炎患者中的变化及意义, objectType=article, longId=30107, objectId=fb973010e4a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fb973010e4a, replyNumber=0, likeNumber=67, createdTime=2014-09-10, rootId=0, userName=amy0550, userId=010d202, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fb973010e4a, moduleTitle=外周血T淋巴细胞CD69在狼疮性肾炎患者中的变化及意义, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=fb973010e4a)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

CD6

2020-05-29

amy0550 (审核中...)

前往app查看评论内容

#CD6#

病例报告：抗CD6抗体治疗COVID-19病人细胞因子释放综合征

2021-10-24

amy0550 (审核中...)

前往app查看评论内容

#CD6#

Br J Cancer：新型CD63–BCAR4融合蛋白可促进肺腺癌的致瘤性和转移

2021-07-26

amy0550 (审核中...)

前往app查看评论内容

#CD6#

Nat Commun：CD318、TSPAN8和CD66c为胰腺癌CAR-T细胞疗法的候选靶标

2021-12-21

amy0550 (审核中...)

前往app查看评论内容

#CD6#

2019年ACR：Equillium发表有关狼疮性肾炎中CD6-ALCAM途径的新见解

2019-11-26

amy0550 (审核中...)

前往app查看评论内容

#CD6#

JCLA：CD62P和P10是评价血液透析治疗终末期肾病疗效的预测指标

2019-06-11

amy0550 (审核中...)

前往app查看评论内容

#CD6#

非控制性哮喘治疗的CD6靶向抗体Itolizumab的Ib期临床试验正式开始

2020-02-04

amy0550 (审核中...)

前往app查看评论内容

#CD6#

Circulation：淋巴细胞上的氧化低密度脂蛋白受体（CD69）可预防动脉粥样硬化，预测亚临床疾病

2019-05-02

amy0550 (审核中...)

前往app查看评论内容

#CD6#

J Exp Med：CD68——抗疟疾药物治疗的新靶点

2015-10-13

amy0550 (审核中...)

前往app查看评论内容

#CD6#

外周血T淋巴细胞CD69在狼疮性肾炎患者中的变化及意义

2014-09-10

科室
- - 订阅+
  - 更多科室
工具
服务